NasdaqGM:MNKDBiotechs
The Bull Case For MannKind (MNKD) Could Change Following FDA Review Of FUROSCIX ReadyFlow Autoinjector
MannKind Corporation recently reported that the FDA accepted its supplemental New Drug Application for the FUROSCIX ReadyFlow Autoinjector, a rapid subcutaneous furosemide delivery device for adults with chronic heart failure or chronic kidney disease, with a PDUFA target action date of July 26, 2026.
If approved, ReadyFlow could meaningfully change at-home management of fluid buildup by cutting administration time from five hours to under 10 seconds while showing bioavailability comparable...